News >

No OS Benefit With Chemoradiotherapy in High-Risk Endometrial Cancer

Jason Harris
Published: Friday, Feb 23, 2018

cervical cancerAdjuvant chemotherapy given during and after radiotherapy did not improve 5-year overall survival (OS) for patients with high-risk endometrial cancer in the phase III PORTEC-3 trial, although the treatment increased failure-free survival (FFS).1

At a median follow-up of 60.2 months (IQR, 48.1-73.1), the 5-year OS was 81.8% (95% CI, 77.5-86.2) with chemoradiotherapy versus 76.7% (95% CI, 72.1-81.6) with radiotherapy (adjusted HR, 0.76, 95% CI, 0.54-1.06; P = .11). Five-year FFS was 75.5% (95% CI, 70.3-79.9) with chemoradiotherapy versus 68.6% (95% CI, 63.1-73.4) with radiotherapy (HR, 0.71, 95% CI, 0.53-0.95; P = .022).

“For each patient [with high-risk endometrial cancer], the cost in terms of increased toxicity and longer treatment duration should be weighed against the benefit in terms of improvement in failure-free survival,” first study author Stephanie M de Boer, MD, department of Radiation Oncology, Leiden University Medical Center, the Netherlands, and coinvestigators wrote.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to PatientOct 31, 20191.5
Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Lung Cancer, Genitourinary Malignancies, and Gynecologic MalignanciesDec 30, 20192.25
Publication Bottom Border
Border Publication